Interleukin-5 Antagonist [EPC]

15407 reported adverse events

Drugs of this class: MEPOLIZUMAB RESLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Antagonist [EPC] class:

# Side effect Count
0 ASTHMA 4535
1 DYSPNOEA 3555
2 WHEEZING 2278
3 COUGH 1845
4 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 1622
5 PNEUMONIA 1451
6 DRUG INEFFECTIVE 1320
7 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 1293
8 BLOOD COUNT ABNORMAL 1092
9 MALAISE 1085
See all common reactions for Interleukin-5 Antagonist [EPC]

Drugs of the Interleukin-5 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 FUNGAL TEST 7 0.7000
1 BRONCHOLITHIASIS 9 0.6923
2 SPUTUM CULTURE 10 0.5000
3 REVERSIBLE AIRWAYS OBSTRUCTION 88 0.4018
4 HEART SOUNDS 14 0.3889
5 AIRWAY REMODELLING 18 0.3830
6 ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME 49 0.3333
7 TOTAL LUNG CAPACITY INCREASED 25 0.3165
8 SMALL AIRWAYS DISEASE 12 0.3158
9 EOSINOPHILIC BRONCHITIS 25 0.2976
See all enriched reactions for Interleukin-5 Antagonist [EPC]